KRAS / RAS targeting: from platform to Phase 3
Chinese groups are not short of G12C molecules (elisrasib’s floor numbers are strong).
Elisrasib showed “robust and durable efficacy” in patients with previously treated locally advanced or metastatic KRAS G12C NSCLC, according to results from an ongoing phase 1/2 trial presented at #AACR26 by
@cbcbc1971
.
Read more:
https://
buff.ly/7DgT2G5
#lcsm #NSCLC
Heat 3 · 1 like · 0 replies · 2 reposts
Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque
Read the abstract →Source: Lung Cancers Today · x.com